| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | — | — | — | — | — | — |
| Quick Ratio | — | — | — | — | — | — |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| ROE | -64.77% | -50.13% | -26.27% | -51.14% | -20.85% | -27.13% |
| ROA | -58.28% | -46.06% | -25.30% | -45.51% | -20.15% | -25.70% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | 4.59 | 4.96 | 10.98 | 4.56 | 6.91 | 3.22 |
Pharvaris N.V. is a biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapies to treat hereditary angioedema (HAE) and other bradykinin B2 receptor-mediated diseases. With its headquarters in Leiden, the Netherlands, Pharvaris is prominently focused on addressing unmet medical needs within the biopharmaceutical industry. The company's key product candidates are designed to provide an oral alternative to injectable therapies for HAE, promising convenience and broader accessibility for patients. Through its research and development efforts, Pharvaris contributes significantly to the healthcare sector by advancing treatment options for rare genetic conditions. Its innovative approach to treatment aims to enhance patient quality of life and improve therapeutic outcomes. As a player in the biotechnology domain, Pharvaris is integral to ongoing developments in genetic and rare disease treatments, reflecting the increasing significance and demand for targeted medicinal solutions in modern healthcare.